Video: High Sensitivity TSO500 Detection

Scientist.com
Published on
November 10, 2020

On November 10, 2020, Discovery Life Sciences’ Dr. Shawn Levy — Chief Scientific Officer of Discovery Life Sciences’ sequencing and bioinformatics laboratory, HudsonAlpha Discovery — presented about some of their latest technologies.

He explained how Discovery Life Sciences has developed a new bundled solution leveraging Illumina’s TruSight Oncology 500 (TSO00) Solid Tumor (FFPE) and cfDNA that delivers actionable, reliable NGS data across matched FFPE tumor and plasma biospecimens and discussed how their services could be used to advance biomarker programs.

You can access the entire presentation recording below, including a very informative Q&A session.

If you have questions for Discovery Life Sciences, email them at genomics@dls.com or access their profile page on Scientist.com .

Interested in hosting a webinar with Scientist.com? Contact us at marketing@scientist.com .

Take the Next Step

1
2
3

Explore Suppliers

Browse trusted partners with relevant expertise

Review Capabilities

Compare services, experience, and past work

Start Your Project

Connect and begin collaborating

Written by
Scientist.com
Share this post

Read Futher

Read Further